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Introduction
Bone is the most common site for metastasis in human
prostate cancer patients. Skeletal metastases are a signifi-
cant cause of morbidity and mortality and overall greatly
affect the quality of life of prostate cancer patients. Despite
advances in our understanding of the biology of primary
prostate tumours, our knowledge of how and why second-
ary tumours derived from prostate cancer cells preferen-
tially localise in bone remains limited. Examining the
impact of these facets of bone metastasis in vivo remains a
significant challenge, as animal models that closely mimic
the natural history and malignant progression of clinical
prostate cancer are not available.
Objectives
To develop an animal model of human metastatic pros-
tate cancer. Once a model has been developed and opti-
mised, it was this to test efficacy of immunotherapy
using T-cells that have been genetically targeted against
prostate-specific membrane antigen (PSMA).
Material and methods
Using PCR, western blot, flow cytometry and ELISA, we
performed functional anaylsis of fucosyltransferase 3
(FT3) in PC3LN3(PL)and PC3LN3-PSMA (PLP) tumour
cell lines. In vivo bioluminescent imaging (BLI) was
used to detect metastases.
Results
In preliminary studies, we have observed that delivery of a
FT3-encoding retroviral vector to PL and PLP enables
them to express sialyl Lewis X and to acquire E-selectin
binding activity. We also showed that FT3 promotes
increased PLP motility and invasiveness in vitro. Biolumi-
nescent animal model of metastasised prostate cancer is
established to determine the effect of this upon their pat-
tern of metastatic spread in SCID Beige mice.
Conclusion
We have established an in-vivo model of PSMA-expressing
prostate cancer. This will serve as a platform to test immu-
notherapy using P28z+ T-cells.
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